无专利的Corbevax承诺疫苗资产

[新德里] Corbevax，一种针对的新疫苗新冠肺炎它的制造商和健康专家说，作为疫苗权益的候选人可能取得了更好的成功，因为它不具有专利，依赖于长期以来的重组技术来制造，并得到了美国和印度政府的支持。

The vaccine already has紧急使用批准据公司发言人称，在印度和海得拉巴的合作者Biogical E Limited将从2月开始每月生产1亿剂。

印度生物技术行业研究援助委员会（BIRAC）helped see Corbevax through the pre-clinical stage and the Phase III clinical studies and is expected to advocate early clearances from the WHO.

Mahima Datla, managing director of Biological E, says once WHO clearances come through, Biological E is confident that it can scale up manufacturing to deliver 300 million doses as promised to the Indian government and an additional one billion doses globally.

Corbevax’s development owed mainly to a long-standing partnership to produce various vaccines between Biological E, the Texas Children’s Hospital Center for Vaccine Development, and the Baylor College of Medicine in Houston, Texas.

Datla说：“多年来，我们共同努力生产质量良好且在世界各地可使用的疫苗。”“鉴于这种背景，我们可以很容易地将Corbevax作为对Covid-19的有效且负担得起的疫苗。”

Srinath Reddy，总裁印度公共卫生基金会，告诉SciDev.Net“ Corbevax易于制造和分发，因为重组技术使用了数十年来生产，例如丙型肝炎疫苗”。

“现在我们需要疫苗资产。我们需要制药公司通过共享许可，专业和技术来与发展中国家保持团结，以便我们所有人都可以从这一大流行中找到出路。”

UN Secretary-General Antonio Guterres

雷迪说，与mRNA和其他几种需要极低冷链的疫苗不同，Corbevax可以在2至8摄氏度的摄入量中存储和运输，允许资源有限的国家存储和分发它。他补充说，这对于现在在印度进行试验的助推器剂量来说是理想的选择。

Biological E affirmed that the vaccine was found to be safe, well-tolerated and immunogenic [capable of building immunity] following the completion of phase III clinical trials involving more than 3,000 subjects between the ages of 18 and 80 at 33 sites across India.

第三阶段的研究表明，与阿斯特拉·泽内卡（Astra-Zeneca）开发的疫苗和牛津大学（Oxford University）开发的疫苗相比，Corbevax刺激了更好的免疫反应，该疫苗是在印度制造的，并且是该国Covid-19免疫计划的中流型。它的不利反应也较少。

Reddy希望Corbevax比大多数现有的疫苗便宜，这主要是因为其主要共同创造者宣布的知识产权豁免，彼得·霍特兹（Peter Hotez）德克萨斯儿童医院疫苗开发中心和贝勒医学院教授的联合主任。

Hotez在12月28日的一条推文中说：“我们技术转移了疫苗，并帮助其与生物E的共同开发，没有专利，也没有附有弦。结果，它应该是最便宜的共同疫苗。”

3. We technology transferred our vaccine and helped in its co-development with BioE with NO PATENT and no strings attached.
4.因此，它应该是最便宜的vid疫苗

- Peter Hotez教授MD博士（@PeterHotez）2021年12月28日

“This vaccine can be made locally all over the world, and we’ve now technology transferred our Texas Children’s vaccine to producers in India, Indonesia, Bangladesh, Botswana. Our Texas Children’s Center does not plan to make money on this, it’s a gift to the world,” Hotez also tweeted.

1月17日，联合国秘书长安东尼奥·古特雷斯（Antonio Guterres）向日内瓦举行的世界经济论坛讲话说the world was “nowhere near the targets” set by the WHO to vaccinate 40 per cent of people in all countries by end 2021 and 70 per cent by the middle of this year.

“Vaccination rates in high-income countries are – shamefully – seven times higher than in African countries,” Guterres said. “We need vaccine equity, now. We need pharmaceutical companies to stand in solidarity with developing countries by sharing licenses, knowhow and technology so we can all find a way out of this pandemic.”

视频来源：United Nations/World Economic Forum。

雷迪说，全世界将不再等待发达国家共享许可并解决专利的竞争。“要使用经过时间测试和安全性的技术（例如用于创建Corbevax的技术）在最短的时间内进行尽可能多的人进行免疫，要好得多。”

Reddy说，Corbevax面对新兴的Covid-19变体（如Omicron），现在在包括印度在内的许多国家 /地区席卷了Omicron，这对于全球疫苗接种计划特别有用。

卫生和家庭福利部在一份声明中说：“我们认为，这种疫苗将满足世界的需求，并帮助全球人口与19日的传播作斗争。”

Emergency use approval for Corbevax was granted in India on 28 December along with similar approval forCovovax, a subunit vaccine developed by the US-based Novovax, licensed to be manufactured by the Serum Institute of India.

印度已经部署的另外两种美国疫苗是ModernA，它使用信使RNA的遗传法（mRNA）来启动免疫系统以对Covid-19的反应，以及单剂量腺病毒载体疫苗的Johnson和Johnson。腺病毒是引起冷或流感样疾病的常见病毒，而向量是灭活的病毒，可以刺激免疫系统产生抗体。

A DNA vaccine produced by the Ahmedabad-based Zydus Cadila calledZycov-Ddoes not need syringes but is administered with a needle-free applicator. DNA vaccines work by transferring a genetically modified blueprint of viral genes into small molecules of DNA or genetic material for injection.

With such an array of COVID-19 vaccines, India has已经覆盖了其合格人口中有90％的首次剂量，第二剂量为65％。

This piece was produced by SciDev.Net’s Asia & Pacific desk.